Insulet is responsible for the European-wide marketing of the Omnipod® Insulin Management System product line

02.07.2018

The Insulet Corporation (NASDAQ: PODD) (Insulet or the Company),
first supplier tubeless
Insulin pumps with the Omnipod insulin management system ^®
(Omnipod System), announced today that the company will start operating on July 1
The marketing of the Omnipod system in Europe resumes for sale,
Sales, Customer Service and Customer Service for the Omnipod System
offer. Insulet has put in place a customer service team specifically for the
will provide world clbad customer support to many customers in Europe.

"We want the diabetes community in Europe now and in the future directly
Said Patrick Sullivan, President and Chief Executive Officer
General manager. "We have an experienced team whose focus is on
an excellent customer experience, and our goal is ours
personalized innovations in the future, even at the European level
Market. "

Since Insulet announced in July 2017, the sale, marketing, the
Training and customer service of the Omnipod system in Europe too
take over, the company has a highly qualified team of over
100 employees to provide the European market with a wide range
Provide expertise in the field of diabetes therapy. Offer also
Insulet now day and night customer service and
Product Support for Over 140,000 Podders ^™ Worldwide
sure.

"For Insulet, customers always came first.
Insulet's marketing in Europe represents a big step forward for
all Omnipod users, "said Eric Renard, professor
Endocrinology at the Lapeyronie University Hospital, Montpellier,
La France. "Insulet enters the diabetes community in Europe
long-term promise, and I look forward to the innovations
they will offer to European customers. "

For more information on the Omnipod system, see
Website of the company.
About the Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative manufacturer of
Medical devices are headquartered in Mbadachusetts. The goal of the company is to
using Omnipod products platform people with diabetes and others
Diseases make life easier. the
Omnipod insulin management system offers a unique alternative to
conventional methods of treatment with insulin. The disposable pod is
a simple portable device that provides continuous administration of insulin on
guaranteed for three days without a needle to handle
needs. Based on the unique design of the Pod developed Insulet
Applications of the Omnipod technology platform also for other subcutaneous
administered drugs. The company was founded in 2000,
And to this day, the omnipod insulin management system has already more
As 140,000 people around the world make their lives easier
and to make it freer.
As of 1 July 2018, Insulet will resume the direct marketing of
Product Line Omnipod Insulin Management System in Europe – Inclusive
Sales, marketing, training and customer service. Insulet is the
The diabetes community in Europe closer and can be European customers
better long-term support – just like in the United States
States and Canada.

For more information, visit: www.insulet.com
and www.myomnipod.com.

Forward-Looking Statements:

This news release may contain forward-looking statements
Statements regarding expectations, badumptions, intentions and beliefs
or future insulet strategies. Such a vision of the future
Statements are based on current expectations and beliefs
Company regarding future developments and their potential
Impact on insulet. There can be no badurance that
future developments affecting Insulet's predictions
sector. Forward-looking statements are subject to a number of
Risks, uncertainties (which in some cases are the control of the
Commercial escape) and other badumptions that may lead to
that actual results or achievements are significantly influenced
The representations of these forward-looking statements differ. Add to that
other risks and uncertainties included in the annual report of the
Company on Form 10-K, February 22, 2018 to
filed with the US Securities and Exchange Commission (SEC)
the heading "Risk factors" (risk factors) as well as in others
currently filed with the SEC. should
risks and uncertainties occur or should
If the badumptions of the company prove to be incorrect, the
the actual results significantly of those in the future
The statements in this document may differ. Insulet takes no
Obligation to publicly update forward-looking statements
or to revise.

View original version on businesswire.com: https://www.businesswire.com/news/home/20180701005020/en/

Stocks on the radar: Infineon Covestro Uniqa Zumtobel Voestalpine .

---

<!- –

Posted in:
Business thread

–

Tagged:

->